GNPX Key Statistics, Chart & Performance
The current stock price of GNPX is 2.83 USD. In the past month the price increased by 32.86%. In the past year, price decreased by -91.91%.
GNPX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GNPX. When comparing the yearly performance of all stocks, GNPX is a bad performer in the overall market: 99.18% of all stocks are doing better.
GNPX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNPX. GNPX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNPX Financial Highlights
Over the last trailing twelve months GNPX reported a non-GAAP Earnings per Share(EPS) of -282. The EPS increased by 70.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -518.59% | ||
| ROE | -1320.11% | ||
| Debt/Equity | 0 |
GNPX Forecast & Estimates
GNPX Ownership
About GNPX
Company Profile
Genprex Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Company Info
GENPREX INC
3300 Bee Cave Road, Suite 650-227
Austin TEXAS 78712 US
CEO: J. Rodney Varner
Employees: 15
Phone: 18777744679
GENPREX INC / GNPX FAQ
What does GENPREX INC do?
Genprex Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2018-03-29. Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The firm's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Can you provide the latest stock price for GENPREX INC?
The current stock price of GNPX is 2.83 USD. The price increased by 0.35% in the last trading session.
Does GNPX stock pay dividends?
GNPX does not pay a dividend.
What is the ChartMill rating of GENPREX INC stock?
GNPX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in GENPREX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNPX.